MARÍA TERESA CABRERA CASTILLO-rekin lankidetzan egindako argitalpenak (72)

2016

  1. Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance

    Cancer Immunology, Immunotherapy, Vol. 65, Núm. 1, pp. 47-59

2013

  1. MHC class i antigens and the tumor microenvironment

    The Tumor Immunoenvironment (Springer Netherlands), pp. 253-286

2012

  1. Cancer immune escape: Implications for immunotherapy, Granada, Spain, October 3-5, 2011

    Cancer Immunology, Immunotherapy

  2. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

    International Journal of Cancer, Vol. 131, Núm. 2, pp. 387-395

2011

  1. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells

    International Journal of Cancer, Vol. 129, Núm. 4, pp. 839-846

  2. Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors

    Immunogenetics, Vol. 63, Núm. 2, pp. 65-71

  3. Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity

    Cancer Immunology, Immunotherapy, Vol. 60, Núm. 6, pp. 869-882

2010

  1. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy

    International Journal of Cancer

  2. Analysis of HLA-ABC locus-specific transcription in normal tissues

    Immunogenetics, Vol. 62, Núm. 11-12, pp. 711-719

  3. Higher HLA class i expression in renal cell carcinoma than in autologous normal tissue

    Tissue Antigens, Vol. 75, Núm. 2, pp. 110-118

2009

  1. HLA and melanoma: Multiple alterations in HLA class i and II expression in human melanoma cell lines from ESTDAB cell bank

    Cancer Immunology, Immunotherapy, Vol. 58, Núm. 9, pp. 1507-1515

2008

  1. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

    Immunogenetics, Vol. 60, Núm. 8, pp. 439-447

  2. HLA class I expression, tumor escape and cancer progression

    Current Cancer Therapy Reviews, Vol. 4, Núm. 2, pp. 105-110

  3. Regressing and progressing metastatic lesions: Resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

    Cancer Immunology, Immunotherapy

2007

  1. Analysis of HLA class I alterations in tumors: Choosing a strategy based on known patterns of underlying molecular mechanisms

    Tissue Antigens

  2. Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours

    Tissue Antigens, Vol. 69, Núm. 3, pp. 220-226

  3. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination

    Cancer Immunology, Immunotherapy, Vol. 56, Núm. 5, pp. 709-717

  4. International conference: Progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain

    Cancer Immunology, Immunotherapy

  5. MHC Class I Antigens and Immune Surveillance in Transformed Cells

    International Review of Cytology, Vol. 256, pp. 139-189

  6. Role of altered expression of HLA class i molecules in cancer progression

    Advances in Experimental Medicine and Biology